Intellia terminates Factor IX co-development agreement with Regeneron; retains milestone/royalty rights under LCA

Intellia Therapeutics, Inc.

On March 19, 2024, Intellia gave notice to Regeneron to exit the Factor IX Co-Development and Co-Funding Agreement, effective after 180 days.
Intellia will no longer share 35% of development costs or receive 35% of profits for Factor IX gene editing products upon termination.
Under the existing License and Collaboration Agreement (LCA), Intellia remains eligible for up to $320M in milestones and high-single to low-teen royalties.
Other collaboration programs with Regeneron under the LCA are unaffected by this termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).

Action: termination
Agreement: collaboration
Counterparty: Regeneron Pharmaceuticals, Inc.
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.

View on SEC.gov

545 material agreements filed in the last 30 days. Browse all material agreements →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-074706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.